Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET

• DOI: 10.1007/s00259-024-06654-5
• Publication Date: 2024-02-24T03:02:29Z
• Authors: Lena Kaiser; S. Quach; A. J. Zounek; B. Wiestler; A. Zatcepin; A. Holzgreve; A. Bollenbacher; L. M. Bartos; V. C. Ruf; G. Böning; N. Thon; J. Herms; M. J. Riemenschne...; S. Stöcklein; M. Brendel; R. Rupprecht; J. C. Tonn; P. Bartenstein; L. von Baumgarten; S. Ziegler; N. L. Albert
• Keywords: Translocator protein; Isocitrate dehydrogenase

According to the World Health Organization classification for tumors of central nervous system, mutation status isocitrate dehydrogenase (IDH) genes has become a major diagnostic discriminator gliomas. Therefore, imaging-based prediction IDH is high interest individual patient management. We compared and evaluated value radiomics derived from dual positron emission tomography (PET) magnetic resonance imaging (MRI) data predict non-invasively.